Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in
combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK)
profiles and clinical efficacy in patients with metastatic hormone-refractory prostate cancer
(HRPC)